Contact Us

Actos Bladder Cancer Lawsuits

The Actos bladder cancer lawyers at Baum, Hedlund, Aristei & Goldman have filed Actos bladder cancer lawsuits in state and federal courts against Takeda Pharmaceuticals, accusing the drug giant of illegally marketing the diabetes medication Actos (pioglitazone) when it knew or should have known that it was associated with an elevated risk of bladder cancer. These lawsuits assert that Takeda negligently failed to warn prescribing doctors and the public of this deadly risk in order to continue profiting from its blockbuster diabetes drug.

The Actos lawsuits have been sparked by injuries and deaths associated with the diabetes medication. According to our Actos complaints, Takeda concealed and continues to conceal their knowledge of Actos’ unreasonably dangerous risks to the public, even after discovering scientific evidence linking Actos to a statistically significant higher risk of bladder cancer.

Takeda and Eli Lilly & Co. launched Actos (pioglitazone) jointly in 1999 and the United States Food and Drug Administration (FDA) approved the drug in July of the same year for the treatment of Type 2 diabetes. Actos belongs to a class of insulin-sensitizing drugs known as thiazolidinediones (commonly referred to as “TZD’s”).

Baum Hedlund’s Actos lawsuits allege that Takeda willingly, wantonly and maliciously suppressed information linking Actos to an increased risk of developing bladder cancer in order to prevent any chance of its product’s registration being delayed or rejected by the FDA.

We allege that Takeda performed preclinical trials prior to FDA approval that showed early signs of a connection between Actos given to lab rats and cancerous tumors. Recently, both Takeda and Actos have become the subjects of mass scrutiny as additional evidence surfaces linking the diabetes medication to bladder cancer.

A recent study found that risk of bladder cancer is 40 percent greater in patients taking Actos for longer than one year, prompting both France and Germany to pull the drug. In the US, the FDA issued a Safety Announcement to inform the public about the link between Type 2 diabetes drug Actos (pioglitazone) and bladder cancer.

How Can We Help?

This field must be blank
Describe your symptoms
Privacy Policy

Actos Whistleblower Lawsuit

The Actos bladder cancer lawyers at Baum Hedlund are also representing medical doctor and whistleblower, Helen Ge, who claims in her whistleblower lawsuit that Takeda, her former employer, failed to report to the FDA clinical trial adverse event data linking bladder cancer to Actos.

This Actos whistleblower lawsuit (Case 1:10-cv-11043-FDS) asserts that Takeda failed to report several hundred Actos adverse events, including bladder cancer events, between late 2007 and 2012, during which time profits continued to soar at Takeda. In 2008 alone, Actos netted profits of $2.4 billion for Takeda, and it has since become one of the highest-selling prescription drugs on the market.